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The use of serum containing polyclonal antibodies from animals immunized with toxins marked the 
beginning of the application of antibody-based therapy in late nineteenth century. Advances in basic 
research led to the development of the hybridoma technology in 1975. Eleven years later, the first 
therapeutic monoclonal antibody (mAb) was approved, and since then, driven by technological advances, 
the development of mAbs has played a prominent role in the pharmaceutical industry. In this review, we 
present the developments to circumvent problems of safety and efficacy arising from the murine origin 
of the first mAbs and generate structures more similar to human antibodies. As of October 2017, there 
are 61 mAbs and 11 Fc-fusion proteins in clinical use. An overview of all mAbs currently approved 
is provided, showing the development of sophisticated mAbs formats that were engineered based 
on the challenges posed by therapeutic indications, including antibody-drug conjugates (ADC) and 
glycoengineered mAbs. In the field of immunotherapy, the use of immunomodulators, bispecific mAbs 
and CAR-T cells are highlighted. As an example of promising therapy to treat infectious diseases, we 
discuss the generation of neutralizing monoclonal-oligoclonal antibodies obtained from human B cells. 
Scientific and technological advances represent mAbs successful translation to the clinic. 
Keywords: Immunotherapy. CDR grafting. Phage display. Transgenic mice. Single B cell sorting.
FROM THE THERAPEUTIC USE OF POLYCLO-
NAL ANTIBODIES TO THE DISCOVERY OF 
MONOCLONAL ANTIBODIES 
The serum therapy introduced by Emil von Behring 
and Shibasaburo Kitasato in the late nineteenth century 
marked the beginning of the application of antibody-
based therapy. They used serum containing polyclonal 
antibodies from animals immunized with diphtheria or 
tetanus toxins to treat these infectious diseases in other 
animals. The collaboration between von Behring and 
Paul Ehrlich resulted in the production of large amounts 
of antisera in animals and the experimental application 
of anti-diphtheria serum in humans, demonstrating the 
efficacy of the serum therapy as an effective antimicrobial 
therapy. Behring awarded the first Nobel Prize for 
Physiology and Medicine in 1901 for his outstanding 
discoveries related to serum therapy especially against 
diphtheria (Kaufmann, 2017) opening a new perspective 
for the clinical handling of infections. The serum therapy 
or passive antibody therapy was largely used until early 
30’s for a wide range of infectious diseases including 
pneumococcal pneumonia, meningococcal meningitis 
and others. Due to the discovery of antibiotics and 
their success for antimicrobial treatment, associated 
to problems of lot to lot variation, toxicity related to 
its heterologous origin and high cost for production, 
the serum therapy was gradually replaced. However, 
animal or human sera still represent a good alternative in 
cases with no available drugs (Casadevall, Dadachova, 
Pirofski, 2004) and unique for the neutralization of 
complex venom mixtures causing envenomation by 
biting accidents. The Instituto Butantan holds a portfolio 
of 13 equine hyperimmune antisera (Instituto Butantan, 
2017). Human blood derivatives also pose limitations for 
wide applications (difficulty of large scale production, 
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risk of disease transmission) and currently human blood 
antibodies are used only for specific purposes, e.g. anti-
Rh for maternal-fetal incompatibility.
From 1940 the science related to antibodies revealed 
important insights such as antibody generation, its structure 
and diversity, Brunet’s clonal selection theory stating 
that one cell produces one specific antibody (Cooper, 
2015). These advances in basic research conducted to the 
development of the breakthrough hybridoma technology 
in 1975 generating hybrid cells secreting rodent-derived 
monoclonal antibodies (mAbs) in unlimited amount 
(Kohler, Milstein, 1975). The hybrid cells were obtained 
by the fusion of B cells originated from immunized animal 
with myeloma cells and the resultant selected single 
cell producing one specific antibody. The hybridoma 
technology awoke the interest for the application of 
antibodies in therapeutics again. However, the main 
targets were not infectious diseases as earlier, being 
directed to other conditions without efficacious drugs. The 
first therapeutic mAb, muromonab, a mAb against CD3 
receptor of T lymphocytes for the control of transplant 
rejection, was approved in 1986 by US Food and Drug 
Administration (FDA) and European Medicines Agency 
(EMA) (Norman et al., 1987). A completely new panorama 
was envisaged for the use of mAbs directed to – as magic 
bullets – a variety of targets, including ones related to 
chronic diseases in need of long term treatments. The 
success of muromonab anti-CD3 did not repeat for other 
indications, failing in safety and/or efficacy. One critical 
issue was the murine nature of the mAbs which induced 
adverse reactions and the immunogenicity response known 
as human anti-mouse antibodies (HAMA), anti-idiotypic 
or not (Hwang, Foote, 2005). 
MAKING POSSIBLE THE USE OF MONOCLO-
NAL ANTIBODIES IN THE CLINIC
To circumvent problems of safety and efficacy, 
decreasing their immunogenic potential, and make 
possible the therapeutic use of antibodies for long 
periods, techniques were developed to transform 
rodent antibodies into structures more similar to human 
antibodies without losing the binding properties to the 
target (Figure 1). Technical advances and knowledge 
increments in molecular biology field that started in 
the 70’s with recombinant DNA technology allowed 
the production of recombinant antibodies by antibody 
engineering technologies (Almagro, Fransson, 2008). The 
first humanization approach led to generation of chimeric 
antibodies by combining sequences of murine variable 
domain with human constant region domain (Morrison et 
al., 1984). The resultant antibody preserved the specificity 
and the immunogenicity was reduced, however still 
observed by the presence of human anti-chimeric antibody 
(HACA) in approximately 40% of patients (Hwang, 
Foote, 2005). Derived from this humanization approach, 
a chimeric anti-GPIIb/IIIa Fab fragment named abciximab 
that inhibits platelet aggregation in cardiovascular diseases 
was approved in 1994 by FDA, representing the second 
therapeutic mAb (Foster, Wiseman, 1998). It was followed 
by anti-CD20 rituximab, a chimeric IgG1 approved for 
non-Hodgkin’s lymphoma in 1997, representing the first 
mAb with oncologic indication (Feugier, 2015). 
One exceptional advance that increased the approval 
of therapeutic mAbs was the generation of humanized 
antibodies by complementary-determining region (CDR) 
grafting technique (Jones et al., 1986). By this technique 
FIGURE 1 – Schematic overview of antibody humanization from murine antibodies (red domains) to fully human antibodies (blue 
domains). Chimeric antibodies are produced by combining sequences of a murine variable domain with human constant region 
domains. The murine CDR sequences transplanted to a human framework sequence produce humanized antibodies by the technique 
known as CDR grafting. Fully human antibodies are expected to be less immunogenic than chimeric and humanized antibodies. 
The images of the immunoglobulin structure (PDB code 1IGY) were created using PYMOL (The PyMOL Molecular Graphics 
System, Version 2.0 Schrödinger, LLC).
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the non-human antibody sequences of the CDR were 
transplanted to a human framework sequence (CDR 
grafting technique) expecting the maintenance of the 
specificity to the target (Jones et al., 1986) (Figure 1). 
To preserve the features of the original antibody such as 
the affinity and potency, this technique was improved by 
application of tridimensional modeling to the humanized 
antibody to identify the rodent residues impacting the 
target binding and so variants of the humanized mAbs 
were designed (Queen et al., 1989). The first CDR-
transplanted humanized mAb approved by FDA in 1997 
was the anti-IL2 receptor daclizumab with indication to 
prevent transplant rejection (Tsurushita, Hinton, Kumar, 
2005). Other humanization techniques were developed 
to generate humanized antibodies (Almagro, Fransson, 
2008), however, CDR grafting was considered the gold 
standard technique for therapeutic mAbs. The presence of 
human anti-humanized antibodies (HAHA) was verified 
in about 9% of humanized antibodies used clinically 
(Hwang, Foote, 2005). The techniques associated with 
antibody humanization turned possible the clinical use 
of a new class of biologics directed to complex diseases 
(autoimmune diseases and tumors) which require a long 
term treatment and also repeated doses of the drugs 
(Watier, Reichert, 2017).
HUMAN MONOCLONAL ANTIBODIES 
FROM PHAGE DISPLAY AND TRANSGENIC 
ANIMALS
Based on the success of humanized mAbs in the 
clinic, discovery technologies to obtain fully human 
mAbs started being developed in early 90’s. At the middle 
of the 80’s it was introduced the technology of in vitro 
display, a discovery platform for recombinant peptides 
and proteins. The first technology was phage display in 
which filamentous bacteriophages incorporated exogenous 
genes with diversity to compose a library, which content 
was presented on the phage surface as a fusion protein 
with a phage coat protein, allowing the selection of 
specific binders and affinity characteristics (Smith, 
1985). This platform was applied for mAbs selection in 
the 90’s using the format of antibody fragments (mainly 
scFv and Fab fragment) by the construction of libraries 
with antibody repertoire from various species, including 
the human repertoire (Figure 2). The main advances of 
this platform were the generation of antibody repertoire 
independent of in vivo immune response; the selection of 
human antibodies; the obtainment of mAbs against any 
kind of antigens such as self-antigens, toxic, unstable and 
non-immunogenic antigens and the possibility of affinity 
maturation of a candidate mAb (Frenzel, Schirrmann, 
Hust, 2016). Phage display technology was also used 
for antibody humanization through the guided selection 
technique. The first fully human therapeutic antibody - 
anti-TNFα adalimumab - derived from this technique, 
was approved in 2002 by FDA for rheumatoid arthritis 
(Osbourn, Groves, Vaughan, 2005). 
Transgenic animals represent another relevant 
discovery technology that started in the 90’s to obtain 
fully human mAbs. Mice were genetically manipulated 
so that human immunoglobulin genes were inserted into 
their genome to replace the endogenous content, turning 
the immune system of these animals capable to synthesize 
fully human antibodies when immunized (Green, 2014). 
The large size of the human immunoglobulin loci was 
a challenge to the transgenic antibody technology. The 
production of similar or comparable repertoires to humans 
in transgenic mice requires diverse rearrangements 
combined with high expression of human V, D and J 
segments (Bruggemann et al., 2015). Different strategies 
have been used successfully to generate animals expressing 
human antibody repertoires (Lonberg et al., 1994; Mendez 
et al., 1997; Murphy et al., 2014). Although the number of 
fully human antibodies from transgenic mice has increased 
rapidly, the amount of platforms with approved drugs has 
remained limited. All the approved mAbs for therapeutic 
use are derived from 3 companies: Abgenix XenoMouse 
(purchased by Amgen in 2005), Medarex UltiMAb and 
HuMAb (purchased by Bristol Myers Squibb in 2009), 
and the more recent Sanofi/Regeneron VelociMouse® 
(LifeSci, 2017). Depending on the immunization protocol 
high affinity human antibodies can be obtained through 
selection of the clones generated mainly by the hybridoma 
technology protocol, after transgenic mice immunization. 
At the early stage of transgenic animal technology the 
targets were antigens with mAbs already in the market 
and the objective was to offer improved antibodies. As an 
example, we can cite the first approved in 2006 by FDA, 
panitumumab (anti-EGFR) followed by ofatumumab 
(anti-CD20). From 2009 mAbs for novel targets gained 
approval. As occurred to other discovery technologies, the 
transgenic mice platforms were improved along the time, 
and this fact contributed for their success, representing 
nowadays more than a half of the approved human mAbs. 
MONOCLONAL ANTIBODIES APPROVED 
TO DATE – CONVENTIONAL AND NEW 
FORMATS
Since the first  therapeutic mAb, driven by 
technological advances, the development of monoclonal 
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antibodies has played a prominent role in the pharmaceutical 
industry. The top 10 best-selling innovative drugs in 2016 
comprised 5 mAbs and 1 Fc-fusion protein that generated 
$53,599 M in worldwide sales (Strohl, 2018). The number 
of mAbs (including Fc-fusion proteins) in late-stages 
clinical studies and approved for clinical use has increased 
rapidly and is expanding to new therapeutic areas. As of 
October 2017, a sum of 61 mAbs and 11 Fc-fusion proteins 
are in the market after been approved by FDA and/or 
EMA (ACTIP, 2017; Lagasse et al., 2017; Strohl, 2018) 
(Figure 3A). A few mAbs approved in the past which were 
withdrawn are not considered in this total. In this review, 
the term “mAbs” includes the Fc-fusion proteins with 
IgG format.
Most of the mAbs currently in the clinic have 
been developed for the treatment of diseases as cancer 
(38.9%), followed by autoimmune (25%), genetic (6.9%), 
infectious (5.5%), asthma (4.2%), cardiovascular (4.2%), 
hematologic (4.2%) and macular degeneration (2.8%). 
Other indications (8.3%) included transplant rejection 
(2.8%), bone loss, antidote, eczema and diabetes type 2 
(Figure 3B). Half of the mAbs (36) in the market are of 
human origin, 18 generated in transgenic animals and 7 
by phage display technology (Bruggemann et al. , 2015; 
Frenzel, Schirrmann, Hust, 2016; LifeSci, 2017), the 
other 11 are Fc-fusion proteins (Figure 3C). Humanized, 
chimeric and murine account for 34.7%, 12.5% and 2.8%, 
respectively, of mAbs in clinical use (Figure 3C).
To date, all of the currently approved mAbs are 
of IgG isotype 1, 2, 4 or hybrid 2/4 (Figure 3D). The 
structure of the immunoglobulin (Ig) is important to 
elicit their function against self or foreign antigens. 
The four IgG subclasses have differences in the hinge 
region and variations in amino acids in the Fc domain 
(Brezski, Georgiou, 2016). The mAbs can interact with 
different Fcγ receptors (FcγRs) depending on the IgG 
subclass, which strongly influences their functional 
activity and pharmacokinetics (PK) (Brezski, Georgiou, 
2016; Wang, Mathieu, Brezski, 2018). IgG1 are the 
preferred IgG subclass for development of therapeutics 
FIGURE 2 – Scheme of phage display technology for the selection of antibody fragments. The antibody library is amplified after 
transformation in E. coli and followed by the infection of helper phage to obtain phages displaying the antibody fragment. The 
phages are transferred to a surface coated with the chosen antigen. Bound phages are eluted and reinfect E.coli for a new selection 
round. After several rounds of the biopanning cycle, individual clones are selected from the enriched library, characterized and 
expressed recombinantly.
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mAbs, representing 80.3% of mAbs currently in clinical 
use, followed by IgG4 (12.7%), IgG2 (5.6%) and one 
hybrid IgG2/4 (1.4%) mAb (Figure 3D). Although 
IgG3 displays the strongest ADCC (antibody-dependent 
cellular cytotoxicity) and CDC (complement-dependent 
cytotoxicity) effector functions of all IgG subclasses, at 
present there is no approved IgG3 mAb; some reasons 
are the relatively short-life compared to the other 
IgG subclasses and the longer hinge that complicates 
bioprocessing (Stapleton et al., 2011; Brezski, Georgiou, 
2016). The serum half-life is ~23 days for IgG1, IgG2 
and IgG4, and 2-6 days for IgG3 (Saxena, Wu, 2016). 
Eculizumab, the IgG2/4 hybrid mAb approved in 2007 
for the treatment of paroxysmal nocturnal hemoglobinuria 
(PNH) relies on this construct to eliminate or reduce the 
effector function via FcγRs and complement binding, 
maintaining normal serum half-life. Considering that 
human IgG2 antibody isotype does not bind FcγRs 
and IgG4 does not activate the complement cascade, 
eculizumab was formed by the CH1 and hinge regions of 
human IgG2 fused to the CH2 and CH3 regions of human 
IgG4 (Rother et al., 2007). 
In relation to size-based structure, antibodies can be 
presented as an entire molecule or fragments. To date, there 
are only 5 antibody-fragments mAbs (6.9%) approved, 4 
antigen-binding fragments (Fab) and 1 single chain variable 
FIGURE 3 – Monoclonal antibodies (including Fc-fusion proteins) currently approved by FDA and/or EMA as of October 2017, 
classified by (A) type of molecule, (B) therapeutic indication, (C) antibody origin and the technology used for the development of 
human mAbs; (D) IgG type, (E) antibody format, (F) antibody structure and (G) host cell.
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fragments (scFv). Full-size mAbs represent 77.8% of the 
mAbs in the clinic and 15.3% are Fc-fusion proteins (Figure 
3E). The development of antibody fragments sought to 
maintain the high specificity and selectivity, while offering 
advantages in manufacturing (time and costs) and additional 
functional benefits such as increased penetration than full-
length mAbs into target tumors or tissues. On the other 
hand, antibody-fragments lacks the Fc domain affecting 
the stability and therapeutic action of mAbs besides shorter 
circulating half-lives (Nelson, 2010). So far, there is only 
one mAb approved in the scFv format - blinatumomab 
- a bispecific T-cell engager (BiTE) antibody against 
CD19/CD3 approved in 2014 for the treatment of acute 
lymphoblastic leukemia (Smits, Sentman, 2016). 
It is important to highlight the use of bispecific 
mAbs for retargeting T cells, in which one arm binds to 
the target cell (usually an antigen on a cancer cell) and 
one arm binds to activating receptors on cytotoxic cells, 
such as T or NK cells (usually T-cell surface glycoprotein 
CD3 ε-chain on T cells) (Weiner, 2015; Strohl, 2018). 
Bispecific antibodies are conceptually old (Davico Bonino 
et al., 1995) and advances in this technology in the past 
decade have led to a significant increase in the number 
of clinical candidates. Chimeric antigen receptor (CAR) 
T cell therapy is another approach employed for T-cell 
redirection to specifically target and destroy tumor cells. 
CAR-T cells are genetically engineered fusion proteins 
formed by a mAb variable region such as scFv, linked 
to a T-cell activating motif (Weiner, 2015; Levine et al., 
2017; Strohl, 2018)(Figure 4). In August 2017, FDA 
approved the first CAR-T cells drug - tisagenlecleucel - 
for the treatment of acute lymphoblastic leukemia (ALL) 
(Kymriah, 2017), and two months later, in October 2017, 
axicabtagene ciloleucel to treat adults with certain types of 
large B-cell lymphoma (Yescarta, 2017). Although these 2 
mAb-related drugs are composed by scFvs, they were not 
considered in Figure 3 because of their particular origin, 
from T-cells of individual patients. Briefly, leukocytes 
are removed from patient’s blood by leukapheresis and 
enriched for T cells, which are engineered to express the 
chimeric antigen receptor (which reprograms the T cells 
to target tumor cells), expanded in a bioreactor system and 
concentrated to a volume that can be infused back into the 
patient (Levine et al., 2017) (Figure 4). 
FIGURE 4 – CAR-T cell therapy. The patient’s immune cells are first collected from the bloodstream by leukapheresis. In vitro, 
these cells are stimulated to express CD8 receptor and engineered by infection with a retrovirus containing genes of the chimeric 
antigen receptor which will be expressed by the TCD8+ cell – this CAR is basically a scFv against the tumor cell target linked to a 
transmembrane domain, a co-stimulatory domain (which enhances the immune response) and a signaling domain (responsible by 
the activation of the T cell) in tandem. The T cells are then expanded over 7-10 days and delivered back to the patient by intravenous 
infusion. Their bind to the tumor cell elicits the immune response leading to tumor death.
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In the  f ie ld  of  cancer  immunotherapy,  an 
extraordinary way of interfering with the immune response 
was proposed by the development of mAbs capable of 
inhibition of immune checkpoints (antagonists of CTLA-
4, PD-1 and PD-L1) that act as immunomodulators (Figure 
5) and can be used as single agent or in combination 
immunotherapy (Emens et al., 2017). By this approach 
the patient own immune response is enhanced to identify 
and destroy tumors in a strategy that can be applied for 
several types of cancers. The first immunomodulator mAb 
approved was the anti-CTL4 ipilimumab for metastatic 
melanoma in 2011 by FDA and EMA. CTL-4 (cytotoxic 
T cell lymphocyte-associated protein 4) inhibits the 
co-stimulatory signal of CD28 and ipilimumab restores 
CD28 activity promoting increase of the number of 
activated T cells that leads to antitumor immune response 
(Ascierto, Marincola, 2014). Currently, there are also 2 
CTLA4-Fc fusion proteins in clinical use: abatacept and 
belacept. Another class of immunotherapy that has been 
approved by FDA and EMA are the inhibitors of either the 
programmed death receptor 1 (PD-1) or its ligand (PD-
L1). PD-1 as well as CTLA4 are expressed on activated 
T cells, with CTLA4 binding to CD80/CD86 on APC 
(antigen presenting cells) and PD-1 binding to PD-L1 on 
tumor cells. These mAbs target and block the inhibitory 
interactions acting as suppressor of the antitumor 
response (Alsaab et al., 2017). To date, 2 anti-PD-1 mAbs 
–pembrolizumab and nivolumab – were approved by 
FDA and EMA in 2014/2015. Later, 3 anti-PD-L1 mAbs 
received marketing authorization from FDA, atezolizumab 
in 2016 and avelumab and durvalumab in 2017 (Alsaab et 
al., 2017; Strohl, 2018) (Figure 5). 
Antibody-drug conjugates (ADCs) emerged as 
a promising anticancer treatment agent combining the 
specificity and selectivity of mAbs with the cytotoxic 
potency of chemotherapy. Although the ADCs have been 
under investigation for decades, recently advances in 
conjugation and linker technologies have enabled the 
development of more stable, effective and safe ADCs 
(Peters, Brown, 2015). Currently, 8.3% of all approved 
mAbs in the clinics are ADCs while the majority (91.7%) 
functions as naked antibodies or in combination with 
chemotherapeutics (Figure 3F). The conjugation to 
exogenous functional moieties is also an alternative used 
to extend the half-life of fragments, which was the strategy 
used in the anti-TNFα PEGylated Fab certolizumab pegol 
(Nelson, 2010). 
MAbs have been produced by a wide variety of 
platforms including mammalian and non-mammalian 
expression systems. The choice of the most appropriate 
platform depends on the protein to be expressed. For 
mAb manufacturing, mammalian expression systems are, 
generally, the preferable choice since such cell lines are able 
to produce large, complex proteins with post-translational 
modifications (PTMs), in special glycosylation. A major 
fraction of the currently mAbs in clinical use was generated 
in Chinese hamster ovary (CHO) cells (62.5%), followed 
by murine myeloma cells NS0 (18%) and Sp2/0 (11.1%), 
FIGURE 5 – MAbs targeting immune checkpoints. The recognition of tumor cells by antigen presenting cells (APCs) leads to T cell 
activation by MHC-antigen interactions with T-cell receptors. CTLA-4 and PD-1 are co-inhibitory checkpoint receptors expressed 
on activated T-cells which downregulate immune response. The binding of CTLA-4 to its ligands CD80/CD86 on APCs and the 
interaction PD-1/PD-L1 on tumor cells result in inhibition of T-cell antitumor response. MAbs targeting CTLA-4 (ipilimumab), 
PD-1 (pembrolizumab and nivolumab) and PD-L1(durvalumab, avelumab and atezolizumab) block these immunoinhibitory 
interactions thus enhancing antitumor response.
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human embryonic kidney 293 (HEK 293) cell line 
(4.2%) and Escherichia coli (4.2%) (Figure 3G). So far, 
the approved mAbs produced in human cells (HEK293) 
are 3 Fc-fusion proteins of the coagulation factors VIII 
(efmoroctocog alfa) and IX (eftrenonacog alfa) for 
the treatment of hemophilia A and B, respectively, and 
glucagon-like peptide-1 (GLP-1) (dulaglutide) for the 
treatment of type 2 diabetes (Dumont et al., 2016). 
Antibody engineering technologies allowed the 
development of mAbs with binding, functional and 
pharmacological characteristics suitable for its therapeutic 
use. Initially the focus of antibody engineering was the 
manipulation of the variable regions for humanization 
and affinity-maturation of antibodies, or the generation 
of different types of antibody fragments such as Fab 
and scFv (Strohl, 2018). Then, the focus turned to the 
improvements of the Fc functions, such as the increase of 
ADCC, ADCP (antibody-dependent cellular phagocytosis) 
and CDC (Brezski, Georgiou, 2016; Strohl, 2018), or the 
silencing of Fc functions (Strohl, 2018). Fc engineering 
has emerged as an important tool for developing mAbs 
with enhanced specific activity and longer half-life, which 
could reduce dosage and potential side effects (Sondermann, 
Szymkowski, 2016). To date, there are 3 approved antibody-
based molecules with reduced Fc functionality and 2 
glycoengineered mAbs with enhanced ADCC activity. The 
CTL4-Fc abatacept and belatacept have modified hinges and 
the anti-C5 mAb eculizumab has a hybrid Fc IgG2/IgG4; all 
of them aiming to reduce Fc functionality to increase safety 
margin as these mAbs bind to immune system components 
(Strohl, 2018). The first glycoengineered mAb to receive 
marketing approval was mogamulizumab, a defucosylated 
anti-CCR4 mAb approved in Japan (under FDA review) 
for patients with relapsed or refractory CCR4-positive 
adult T-cell leukemia-lymphoma. The depletion of fucose 
residues – which are responsible for adverse effects on 
antibodies’ effector function – from oligosaccharides in the 
antibody Fc region has shown to enhance mogamulizumab 
ADCC activity by up to 100 fold (Beck, Reichert, 2012). 
Obinutuzumab, an anti-CD20 mAb with low fucose content, 
was approved by FDA and EMA for the treatment of chronic 
lymphocytic leukemia (CLL) (Golay et al., 2013).
NEUTRALIZING MONOCLONAL-OLIGO-
CLONAL ANTIBODIES TO TREAT INFEC-
TIOUS DISEASES 
It draws attention when analyzing the approved 
mAbs that the majority target cancer and autoimmune 
diseases, while some are directed to other conditions and 
very few address infectious diseases. To treat infectious 
diseases the direct isolation of antibodies from humans 
instead of humanization from other animals is preferred 
wherever possible. Human B cells are nowadays largely and 
commonly used as starting material to isolate human mAbs 
through methodologies such as in vitro display techniques, 
B cells immortalization and single B cell expression cloning 
(Wilson, Andrews, 2012). Neutralizing human antibodies 
to fight infectious agents are potentially more efficient if 
derived directly from human B lymphocytes, as heavy 
chain and light chain pairing is already selected in vivo after 
rearrangement and have been tolerized in humans, either 
following infection or vaccination. There are currently two 
major approaches to secure the production of human mAbs 
derived from B lymphocytes, by the immortalization of 
selected B cells and/or the capture and sorting of specific B 
cells followed by amplification of the mAb variable chains 
expressed by the single B cell. Attempts of immortalization 
of B lymphocytes with the lymphotropic herpesvirus 
Epstein-Barr virus (EBV), converting the normal B cells 
into established cell line, started soon after the hybridoma 
technology discovery. Its potential was hampered by 
major issues like the source of human lymphocytes, the 
lack of a suitable human myeloma fusion partner and the 
instability of EBV transformed B cells. Twenty years ago 
we tried to obtain human mAbs from splenocytes derived 
from a spherocytosis patient, who had undergone several 
blood transfusions and eventually splenectomy. The 
overall EBV infection efficiency was very high and the 
cells were submitted to cloning by limiting dilution. The 
supernatants of primary cultures were assayed by indirect 
immunofluorescence against a panel of several human cell 
lines and primary cells, resting or activated. One of the 
clones produced an IgM/Κ antibody that was identified 
by several criteria to be an anti-Tn antigen, reacting with 
both Tnα and β antigens, when tested against a panel of 
glycoproteins by ELISA. As Tn being a surface antigen in 
many tumors, a small number of tumor cell lines was tested, 
resulting positive by immunohistochemical staining for 
A549 (lung tumor). The efforts to hybridize the clone with 
human K6H6 heteromyeloma were unsuccessful and after 
4 months there was decay in mAb production, albeit the 
cells continued to grow vigorously (Moro AM, unpublished 
results).
The major source of human B lymphocytes however 
is the peripheral blood which not always contains 
memory cells preferentially allocated in lymphoid 
organs. Unfruitful trials were made to immunize human 
peripheral blood cells in vitro, either to present the antigen 
or to improve the binding affinity. Although a suitable 
human myeloma fusion partner was never successfully 
established, some groups obtained stable human mAbs 
Advances and challenges in therapeutic monoclonal antibodies drug development
Braz. J. Pharm. Sci. 2018;54(Special):e01007 9
producing hybridomas after fusion of EBV transformed 
cells with non-secreting murine-human heteromyelomas, 
e.g., HMMA 2.5 (Gorny, 2012). Electrofusing EBV 
transformed B cells to the HMMA 2.5 heteromyeloma 
was an efficient way for Yu et al. (2008) to obtain 
human neutralizing mAbs from elderly people that had 
survived the 1918 influenza pandemia. Rescuing specific 
B cells from peripheral blood with recombinant 1918 
haemagglutinin protein antigen in 8 out of 32 candidates 
after nearly 90 years proved the occurrence of functional 
adaptive immunity to the pandemic virus (Yu et al., 2008). 
A recent technology is based on the expression of the 
antibody heavy and light genes captured from a single B 
lymphocyte, through the protocol of immunophenotyping, 
cell sorting, RT-PCR (reverse transcriptase polymerase 
chain reaction), sequencing, cloning in plasmids containing 
the gene sequences of light and heavy constant chains and 
transfection into mammalian cells (Scheid et al., 2009). 
Taking advantage of both techniques, some groups have 
combined EBV transformation of B cells and recombinant 
expression of derived mAbs as a practice to express mAbs 
targeting influenza viruses. To understand and evaluate 
the immunization efficacy of influenza viruses vaccine, 
heterosubtypic neutralizing mAbs were obtained by first 
sorting out B cells from individuals vaccinated against 
seasonal influenza following by the transformation of the 
specific B cells with EBV virus (Corti et al., 2010). The 
transforming of these single B cells meant to avoid the large 
work of RT-PCR amplification of both light and heavy chain 
genes for each B cell, sequencing, cloning and transfecting 
into a mammalian cell. Another complex combination of 
techniques gave rise to a mAb that recognizes a novel and 
conserved epitope on the globular head of H1N1 virus 
haemagglutinin. In this case, human peripheral blood 
mononuclear cells were transformed with EBV virus with 
additives for efficiency enhancement and the selected B 
cells were fused to HMMA2.5 heteromyeloma following 
by limiting dilution cloning. The mRNA of the hybridomas 
was extracted with selected primers, cDNA was prepared, 
amplified and cloned into mammalian cells for recombinant 
expression (Krause et al., 2011). 
Besides the potential for therapy, human mAbs from 
vaccinated or infected individuals offer the opportunity to 
gain knowledge on how the immune system responds to 
one or other situation and how vaccines can be developed 
or improved to add efficiency and safety to immunized 
populations. The study of clonal lineages and amplitude 
of influenza neutralization found in repertoires of infected 
and vaccinated individuals could provide guidance 
for design of influenza vaccines capable of inducing 
immunodominant broadly cross-reactive antibody 
responses (Moody et al., 2011). The new approved 
composition of 4 monovalent viruses to influenza 
vaccination was proposed by Lee et al. (2016) due to the 
results found in the serological repertoire elicited to each 
of the 3 monovalent components evaluated in pre- and 
post-vaccination samples, through a new technological 
approach which combines high-resolution proteomics 
analysis of immunoglobulins (Ig-seq) and high-throughput 
sequencing of transcripts encoding B cell receptors 
(BCR-seq) (Lee et al., 2016). In the case of influenza, 
neutralizing antibodies can be captured either from 
vaccinated or infected people, even rescuing responses to 
the 1918 pandemia (Yu et al., 2008). 
The case of viral infections with no available 
vaccines as HIV and arboviruses, poses interesting 
and intriguing scientific questions: a few HIV chronic 
infected individuals never develops AIDS and 4 serotypes 
of dengue viruses elicit neutralizing and enhancing 
antibodies. Different neutralizing human anti-HIV mAbs 
were reported in recent years, giving a promise for 
treatment, vaccine design and eradication, reviewed by 
Stephenson and Barouch (Stephenson, Barouch, 2016). 
High affinity mAbs obtained from B cells from chronically 
infected people have matured in vivo against different viral 
epitopes, CD4 cells binding site, glycan-dependent site 
on the virus envelope. The Fc functionality, mediating 
the killing of infected cells has been demonstrated 
as an important feature of the neutralizing anti-HIV 
mAbs. Different mAb candidates have been screened in 
preclinical and/or clinical studies so far, showing good 
tolerability and potency (Stephenson, Barouch, 2016).
Neutralizing mAbs against arboviruses have been 
generated from B cells of infected convalescent people. 
Using a double screening to capture B cells committed 
to make antibodies against dengue viruses, Smith et al. 
obtained 50 human mAbs exhibiting different unique 
neutralization potencies, binding to different sites and also 
enhancing mAbs which can be of great value in rational 
dengue viruses vaccine design (Smith et al., 2014). 
Human mAbs obtained by B cells of naturally infected 
people are under in vivo testing in mice, demonstrating 
protection for Chikungunya virus (Fric et al., 2013). 
Highly neutralizing human mAbs just described have the 
potential for impeding the maternal-fetal transmission of 
Zika virus (Robbiani et al., 2017).
TECHNOLOGICAL CHALLENGES TO PRO-
DUCE BETTER ANTIBODIES
Therapeutic mAbs, albeit highly efficient as magic 
bullets, are not devoid of occurrence of adverse reactions 
M. L. Santos, W. Quintilio, T. M. Manieri, L. R. Tsuruta, A. M. Moro
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in patients. From just transient anti-drug antibodies (ADA) 
without any clinical relevance to serious effects including 
anaphylaxis and premature drug clearance interfering in the 
drug PK properties (Chirmule, Jawa, Meibohm, 2012), the 
immunological effects of mAbs may be caused by several 
factors, either patient’s or drug related: genetic background, 
previous immunity, drug schedule, manufacturing process, 
formulation and molecular characteristics (Jefferis, 2016). 
Fully human monoclonal antibodies are conceptually less 
immunogenic than chimeric or humanized. However, 
adalimumab, e.g., is known to induce ADA in up to 30% 
of the patients (Bartelds et al., 2007; Goupille, 2016). In 
this case, these responses can be T-cells dependent, i.e. 
small linear sequences (9-mer) in the therapeutic protein 
may bind to the major compatibility complex activating 
the presentation to the compatible cells thus eliciting the 
immunogenic response. In this context, there are many 
approaches to identify and suppress CD4+ T cell epitopes 
within the protein sequence. According to a search on the 
online tool PubMed, from January 2012 to November 2017 
using the keywords “T-cell epitope prediction” 209 articles 
were found from vaccine design to therapeutic proteins 
deimmunization. In silico processes are based in computer 
algorithms able to analyze the protein sequences mapping 
the MHC-I and II restricted T cell epitopes (Weber et al., 
2009; Delluc, Ravot, Maillere, 2011). Ex vivo identification 
of CD4+ T epitopes has been successfully applied to 
identify the immunogenic sequences in infliximab and 
rituximab (Hamze et al., 2017) both chimeric monoclonal 
antibodies. Once identified, epitopes may be engineered as 
a less immunogenic molecule.
The optimization of the binding epitope relies mainly 
in the right selection during the antibody selection step. 
In vivo, this affinity maturation depends on and is limited 
to response to the antigen (Batista, Neuberger, 1998) and 
improvements in the affinity can be achieved by the called 
in vitro affinity maturation, including random or targeted 
mutagenesis (Chowdhury, 2003) and shuffling approach 
(Schmohl et al., 2017) to manipulate DNA sequence and 
obtain a panel of antibodies with different affinities from 
the parental molecule. After, the selected molecule may 
be optimized to increase the binding affinity. In silico 
molecular modelling is an important tool to simulate the 
interaction to the target and then identify the candidate 
amino-acid for replacement to increase the binding (Balint, 
Larrick, 1993; Lamdan et al., 2013). Moreover, the affinity 
may be tailored considering the electrostatic interaction 
between mAb and antigen to increase affinity up to 140-
fold (Lippow, Wittrup, Tidor, 2007).
Although engineered mAbs have been showing 
better functional characteristics, the stability of these drugs 
is still a matter of concern. There are two ways mostly used 
for stabilizing a protein-based drug. The first one is the 
improvement of the formulation conditions by addition 
of stabilizers, as surfactants (Agarkhed et al., 2018); 
the second and widely studied strategy is to improve the 
molecule structure through protein engineering. By the 
introduction of N-glycan sites on the constant region of the 
Fab domain of bevacizumab, the resulting glycosylation 
was found to stabilize the protein structure without activity 
loss (Courtois et al., 2016). The strategy is to identify the 
key spots for mutation. Substitutions of native for charged 
amino acids were seen to increase the thermal stability of 
proteins. This tool emerged as a powerful methodology, 
with the caution that mutations can also result in negative 
effects caused by unexpected changes in the activity 
of the molecule (Lawrence, Phillips, Liu, 2007). By 
structure-based computational design methods, theoretical 
approaches have been used to predict unwanted events and 
consequently focus only on beneficial substitutions. This 
method uses existing or predicted protein structures to 
identify aggregation-prone regions (Chennamsetty et al., 
2009) along with molecular biology techniques resulting 
in the creation of new antibodies (Miklos et al., 2012; De 
Nardis et al., 2017) and also biobetters, improved versions 
of original mAbs (Courtois et al., 2016).
PERSPECTIVES
Antibody-based therapy has continuously evolved 
since the initial discovery. Nowadays therapeutic mAbs 
represent the principal biological drugs in development, in 
clinical trials and in the market. It is clear that mAbs and 
fusion proteins play a leading role in the pharmaceutical 
industry and market. A recent review (Strohl, 2018) that 
compiled the number of mAbs in clinical studies showed 
575 in Phase I/II and 70 in Phase III. Only for bispecific 
formats, there are at least 61 in clinical trials, generated 
through not less than 24 different technology platforms 
(Strohl, 2018). The ability to engineer mAbs to fine-tune 
their properties for nearly any application has opened 
a promising horizon for this class of therapeutic drugs. 
Their use revolutionized the treatment of human diseases 
acting in various kinds of targets and mechanisms. 
Novel discovery technologies and antibody engineering 
techniques are being developed and existing technologies 
have been improved to obtain new therapeutic mAbs. 
The expectation is that in the near future new mAbs 
will be approved giving more potent treatment options 
for the patients. Targets unexplored until recently might 
make striking differences with mAbs in advanced stages 
of evaluation for new therapeutic indications such as 
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Alzheimer’s disease (Rygiel, 2016), which urgently needs 
new treatment alternatives. 
In addition to the innovative mAbs, the biosimilars 
versions are growing rapidly powered by patent 
expiration of blockbusters mAbs such as the best-selling 
anti-TNFα adalimumab, with worldwide sales of 16 
billion dollars in 2016 (Strohl, 2018). To date, from the 
11 biosimilar mAbs approved by the FDA and/or EMA, 
7 of them are anti-TNFα drugs. The most recent approval 
was on December 1, 2017 by the FDA of the biosimilar 
version of trastuzumab for the treatment of breast and 
stomach cancers (Ogivri, 2017). This is the second 
biosimilar approved in the U.S., after bevacizumab for 
treatment of cancer and the first for these two types of 
tumor (Mvasi, 2017). The approval of biosimilars by 
regulatory agencies depends on the demonstration of 
no clinically significant differences in safety, purity and 
potency compared to the reference product. Differences 
in the glycosylation pattern usually occurs and must be 
proven to be clinically irrelevant (Tsuruta, Lopes Dos 
Santos, Moro, 2015). 
Considering the expression system, most of the 
approved mAbs are expressed by rodent cells. Human 
cell lines able to accomplish complete human post 
translation modified proteins as HEK cells had Fc-fusion 
drugs approved more recently. The PER.C6 cells, of 
human origin as well, have been used in the development 
of innovator mAbs (Lopes dos Santos et al., 2013; 
Tsuruta et al., 2016). Parallel developments claim that 
plants might represent increased production capacity 
and, trying to surpass immunogenic potential, plant cells 
have been engineered to express human transferases 
(Komarova et al., 2017). Z-mapp, a product consisting 
of a combination of 3 humanized mAbs targeting Ebola 
virus was produced in tobacco plant and used on a 
compassionate basis during the Ebola epidemics in 
Africa (Chen, Davis, 2016). Yet to reach therapeutically 
less accessible or cryptic epitopes to conventional 
antibody formats, the atypical paratope of camelids 
and bovines, displaying unique structure features, have 
gained interest and studies for humanizing these formats 
are in course (Muyldermans, Smider, 2016). 
A recent approach for the clinical use of mAbs 
relies on the combination of antibodies – oligoclonal 
mixtures – usually against a single target related to cancer 
or infectious diseases (Ellebaek et al., 2016; Strohl, 2018). 
Several studies indicate the synergistic effect of individual 
mAbs to enhance the virus or toxins neutralization, 
somehow playing the same role as polyclonal antibodies 
selected in vivo to fight infections. A mix of anti-HIV 
neutralizing mAbs obtained by different laboratories is 
under preclinical testing (Stephenson, Barouch, 2016). 
MAbs cocktails could potentially be administered at 
lower doses, reducing costs while increasing efficacy and 
safety (Diamant et al., 2015). The combination of mAbs 
into a single product aims to overcome heterogeneity and 
plasticity of antigens (Corti, Kearns, 2016). 
Antibody therapy has come a long way since the 
approval of the first murine mAb in 1986. Public and 
private investments in mAb-based therapy have never 
been so great, and the speed of progress not so fast 
as nowadays. For the 74 currently approved mAbs, 
considering 11 Fc-fusion proteins and 2 CAR-T cells, 7 
(9.5%) were approved in the 90’s, 18 (24.3%) from 2000 
to 2010 and 49 (66.2%) received marketing authorization 
since 2011, with 29 of them (59.2%) in the last 3 years 
(2015-2017). This spectacular scenario holds promise for 
a steady growth in therapeutic possibilities. 
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